Evaluation of Brucella Abortus Phosphoglucomutase (pgm) Mutant As a New Live Rough-phenotype Vaccine

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2003 Oct 24

PMID 14573645

Citations 36

Authors

Juan Esteban Ugalde

Diego Jose Comerci

M Susana Leguizamon

Rodolfo Augusto Ugalde

Affiliations

Soon will be listed here.

Abstract

Brucella abortus S19 is the vaccine most frequently used against bovine brucellosis. Although it induces good protection levels, it cannot be administered to pregnant cattle, revaccination is not advised due to interference in the discrimination between infected and vaccinated animals during immune-screening procedures, and the vaccine is virulent for humans. Due to these reasons, there is a continuous search for new bovine vaccine candidates that may confer protection levels comparable to those conferred by S19 but without its disadvantages. A previous study characterized the phenotype associated with the phosphoglucomutase (pgm) gene disruption in Brucella abortus S2308, as well as the possible role for the smooth lipopolysaccharide (LPS) in virulence and intracellular multiplication in HeLa cells (J. E. Ugalde, C. Czibener, M. F. Feldman, and R. A. Ugalde, Infect. Immun. 68:5716-5723, 2000). In this report, we analyze the protection, proliferative response, and cytokine production induced in BALB/c mice by a deltapgm deletion strain. We show that this strain synthesizes O antigen with a size of approximately 45 kDa but is rough. This is due to the fact that the deltapgm strain is unable to assemble the O side chain in the complete LPS. Vaccination with the deltapgm strain induced protection levels comparable to those induced by S19 and generated a proliferative splenocyte response and a cytokine profile typical of a Th1 response. On the other hand, we were unable to detect a specific anti-O-antigen antibody response by using the fluorescence polarization assay. In view of these results, the possibility that the deltapgm mutant could be used as a vaccination strain is discussed.

Citing Articles

Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives.

Dawood A, Elrashedy A, Nayel M, Salama A, Guo A, Zhao G Front Vet Sci. 2023; 10:1255239.

PMID: 37876633 PMC: 10591102. DOI: 10.3389/fvets.2023.1255239.

Inflammatory Mechanism of Infection in Placental Trophoblast Cells.

Xiao Y, Li M, Guo X, Zeng H, Shuai X, Guo J Int J Mol Sci. 2022; 23(21).

PMID: 36362199 PMC: 9657658. DOI: 10.3390/ijms232113417.

The regulon of Brucella abortus two-component system BvrR/BvrS reveals the coordination of metabolic pathways required for intracellular life.

Rivas-Solano O, Van der Henst M, Castillo-Zeledon A, Suarez-Esquivel M, Munoz-Vargas L, Capitan-Barrios Z PLoS One. 2022; 17(9):e0274397.

PMID: 36129877 PMC: 9491525. DOI: 10.1371/journal.pone.0274397.

Combined immunization with inactivated vaccine reduces the dose of live B. abortus A19 vaccine.

He C, Zhang Y, Liu M, Zhao H, Ren L, Liu B BMC Vet Res. 2022; 18(1):128.

PMID: 35366881 PMC: 8976406. DOI: 10.1186/s12917-022-03229-0.

Design and Characterization of a Recombinant RB51 Vaccine That Elicits Enhanced T Cell-Mediated Immune Response.

Sarmadi M, Gheibi A, Khanahmad H, Khorramizadeh M, Hejazi S, Zahedi N Vaccines (Basel). 2022; 10(3).

PMID: 35335018 PMC: 8950781. DOI: 10.3390/vaccines10030388.

References

Vemulapalli R, He Y, Buccolo L, Boyle S, Sriranganathan N, Schurig G . Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infect Immun. 2000; 68(7):3927-32. PMC: 101669. DOI: 10.1128/IAI.68.7.3927-3932.2000. View

Forestier C, Moreno E, Pizarro-Cerda J, Gorvel J . Lysosomal accumulation and recycling of lipopolysaccharide to the cell surface of murine macrophages, an in vitro and in vivo study. J Immunol. 1999; 162(11):6784-91. View

Ugalde J, Czibener C, Feldman M, Ugalde R . Identification and characterization of the Brucella abortus phosphoglucomutase gene: role of lipopolysaccharide in virulence and intracellular multiplication. Infect Immun. 2000; 68(10):5716-23. PMC: 101528. DOI: 10.1128/IAI.68.10.5716-5723.2000. View

Briones G, Inon de Iannino N, Roset M, Vigliocco A, Paulo P, Ugalde R . Brucella abortus cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells. Infect Immun. 2001; 69(7):4528-35. PMC: 98529. DOI: 10.1128/IAI.69.7.4528-4535.2001. View

Delvecchio V, Kapatral V, Redkar R, Patra G, Mujer C, Los T . The genome sequence of the facultative intracellular pathogen Brucella melitensis. Proc Natl Acad Sci U S A. 2002; 99(1):443-8. PMC: 117579. DOI: 10.1073/pnas.221575398. View

Paulsen I, Seshadri R, Nelson K, Eisen J, Heidelberg J, Read T . The Brucella suis genome reveals fundamental similarities between animal and plant pathogens and symbionts. Proc Natl Acad Sci U S A. 2002; 99(20):13148-53. PMC: 130601. DOI: 10.1073/pnas.192319099. View

Schurig G, Sriranganathan N, Corbel M . Brucellosis vaccines: past, present and future. Vet Microbiol. 2002; 90(1-4):479-96. DOI: 10.1016/s0378-1135(02)00255-9. View

Porte F, Naroeni A, Ouahrani-Bettache S, Liautard J . Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect Immun. 2003; 71(3):1481-90. PMC: 148865. DOI: 10.1128/IAI.71.3.1481-1490.2003. View

Fernandez-Prada C, Zelazowska E, Nikolich M, Hadfield T, Roop 2nd R, Robertson G . Interactions between Brucella melitensis and human phagocytes: bacterial surface O-Polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect Immun. 2003; 71(4):2110-9. PMC: 152029. DOI: 10.1128/IAI.71.4.2110-2119.2003. View

10.

Moreno E, Speth S, Jones L, BERMAN D . Immunochemical characterization of Brucella lipopolysaccharides and polysaccharides. Infect Immun. 1981; 31(1):214-22. PMC: 351772. DOI: 10.1128/iai.31.1.214-222.1981. View

11.

Angus R, Barton C . The production and evaluation of a buffered plate antigen for use in a presumptive test for brucellosis. Dev Biol Stand. 1984; 56:349-56. View

12.

Caroff M, Bundle D, Perry M, Cherwonogrodzky J, Duncan J . Antigenic S-type lipopolysaccharide of Brucella abortus 1119-3. Infect Immun. 1984; 46(2):384-8. PMC: 261543. DOI: 10.1128/iai.46.2.384-388.1984. View

13.

Ried J, Collmer A . An nptI-sacB-sacR cartridge for constructing directed, unmarked mutations in gram-negative bacteria by marker exchange-eviction mutagenesis. Gene. 1987; 57(2-3):239-46. DOI: 10.1016/0378-1119(87)90127-2. View

14.

Smith L, Ficht T . Pathogenesis of Brucella. Crit Rev Microbiol. 1990; 17(3):209-30. DOI: 10.3109/10408419009105726. View

15.

Schurig G, Roop 2nd R, Bagchi T, Boyle S, Buhrman D, Sriranganathan N . Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol. 1991; 28(2):171-88. DOI: 10.1016/0378-1135(91)90091-s. View

16.

Jiang X, Baldwin C . Effects of cytokines on intracellular growth of Brucella abortus. Infect Immun. 1993; 61(1):124-34. PMC: 302696. DOI: 10.1128/iai.61.1.124-134.1993. View

17.

Schafer A, Tauch A, Jager W, Kalinowski J, Thierbach G, Puhler A . Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum. Gene. 1994; 145(1):69-73. DOI: 10.1016/0378-1119(94)90324-7. View

18.

Nielsen K, Kelly L, Gall D, Nicoletti P, Kelly W . Improved competitive enzyme immunoassay for the diagnosis of bovine brucellosis. Vet Immunol Immunopathol. 1995; 46(3-4):285-91. DOI: 10.1016/0165-2427(94)05361-u. View

19.

Lin M, Nielsen K . Binding of the Brucella abortus lipopolysaccharide O-chain fragment to a monoclonal antibody. Quantitative analysis by fluorescence quenching and polarization. J Biol Chem. 1997; 272(5):2821-7. DOI: 10.1074/jbc.272.5.2821. View

20.

Corbel M . Brucellosis: an overview. Emerg Infect Dis. 1997; 3(2):213-21. PMC: 2627605. DOI: 10.3201/eid0302.970219. View